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Abstract
Background: To investigate the frequency of achievement of inactive disease (ID) in children with juvenile
idiopathic arthritis (JIA) treated with methotrexate (MTX) as the sole disease-modifyng antirheumatic (DMARD)
therapy and to develop a prediction model for lack of attainment of ID.
Methods: The clinical charts of consecutive patients started with MTX as the sole DMARD between 2000 and 2013
were reviewed. Patient follow-up was censored at first episode of ID or, in case ID was not reached, at last follow-
up visit or when a biologic DMARD was prescribed. The characteristic at MTX start of patients who achieved or did
not achieve ID were compared with univariate and multivariable analyses. Regression coefficients (β) of variables
that entered the best-fitting logistic regression model were converted and summed to obtain a “prediction score”
for lack of achievement of ID.
Results: A total of 375 patients were included in the study. During MTX administration, 8.8% were given systemic
corticosteroids and 44.1% intra-articular corticosteroids. After MTX start, 229 (61%) patients achieved ID after a
median of 1.7 years, whereas 146 patients (39%) did not reach ID after a median of 1.2 years. On multivariable
analysis, independent correlations with lack of achievement of ID were identified for the disease categories of
systemic arthritis, enthesitis-related arthritis (ERA) and polyarthritis and C-reactive protein (CRP) > 1.4 mg/dl. The
prediction score ranged from 0 to 3 and its cutoff that discriminated best between patients who achieved or did
not achieve ID was > 0.5. The categories of systemic arthritis or ERA, both of which had a score greater than 0.5,
were sufficient alone to predict a lower likelihood to reach ID. Polyarthritis and increased CRP, whose score was 0.5,
assumed a predictive value only when present in association.
Conclusion: A conventional treatment regimen based on MTX as the sole DMARD led to achievement of ID in a
sizeable proportion of children with JIA. Our findings help to outline the characteristics of patients who may
deserve a synthetic DMARD other than MTX or the introduction of a biologic DMARD from disease outset.
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Background
Juvenile idiopathic arthritis (JIA) is a chronic and het-
erogeneous disease characterized by prolonged synovial
inflammation that may cause irreversible alterations of
articular structures [1]. Joint changes can lead to serious
impairment of physical function and have a major im-
pact on the quality of life of children and their families
[2–4]. It is now well established that minimizing disease
activity over time reduces progression of joint damage
and improves functional outcome in patients with
chronic arthritis [5–7]. These observations, together
with the recent therapeutic progress, have moved the
therapeutic aims increasingly towards the attainment of
an inactive disease status [8–10].
Methotrexate (MTX) is the cornerstone synthetic dis-
ease-modifying antirheumatic drug (DMARD) for the
treatment of JIA [11–13]. It is an inexpensive and safe
medication, and has been shown to be beneficial in 60–70%
of patients both in randomized controlled trials and obser-
vational studies [14–17]. However, most analyses have
evaluated the effectiveness of MTX in terms of percentage
of improvement in clinical and laboratory indices of disease
activity, whereas its capacity to induce complete disease
quiescence has been seldom investigated [18–20].
Considering that current clinical practice mandates good
overall disease control, to gain further insight into the
therapeutic efficacy of MTX there is a need to obtain more
information about its disease-remitting potential.
Because it is still impossible to predict the disease
course in the individual patient and, hence, the treat-
ment requirements at the onset of the disease [13, 21], a
step-up approach is generally pursued of starting MTX
and adding a biologic DMARD if the patient does not
respond sufficiently well to MTX. However, given the
abovementioned goal to start effective treatment imme-
diately in order to prevent joint damage and the notion
that MTX is not efficacious in a sizeable proportion of
patients, it is essential to distinguish beforehand the pa-
tients who are likely to respond well to MTX from those
who are not. The latter group may deserve prescription
of a biologic DMARD from the outset. Over the years,
several studies have sought for predictors of MTX
efficacy. However, most of them have focused on the
American College of Rheumatology (ACR) pediatric
level of response (which emphasize percentage change),
whereas the achievement of the state of inactive disease
(ID) has rarely been used as endpoint [13, 22, 23].
Against this background, the primary aim of the
present study was two-fold. First, we investigated the
frequency of achievement of ID in children with JIA
treated with MTX as the sole DMARD. Second, we
aimed to develop a prediction model that could help to
identify at treatment baseline the patients with a lesser
likelihood to reach ID with MTX.
Methods
Study design and patient selection
All consecutive patients who met the International
League of Associations for Rheumatology (ILAR) criteria
for JIA [24], were started with MTX as the sole DMARD
at the Istituto G. Gaslini of Genoa, Italy between 2000
and 2013, and had a minimum follow-up of 6 months
after treatment initiation, were included in the study. Pa-
tients previously treated with any biologic DMARD were
excluded. Previous treatment with other synthetic
DMARDs or concomitant or previous administration of
nonsteroidal anti-inflammatory drugs and systemic or
intra-articular corticosteroids was allowed. The analysis
was conducted through the retrospective review of pa-
tient clinical charts and data stored in clinical databases.
Patient information was collected by means of standard-
ized case report forms and was entered in a specialized
database. The study protocol was approved by the ethics
committee of the Istituto G. Gaslini, Genoa, Italy.
Protocol of MTX administration
MTX was given orally or subcutaneously at the dosage
of 10–15 mg/m2/week (maximum 25mg/week) in a sin-
gle weekly dose. All patients received folate supplemen-
tation with folinic acid at 25–50% of MTX dose the day
after MTX administration. During MTX therapy, pa-
tients were evaluated clinically every 3 to 6 months. La-
boratory monitoring was carried out every 8–12 weeks.
Assessment of ID
For each patient, all visits from the start of MTX therapy
to the last follow-up evaluation in which the patient was
still receiving MTX as the sole DMARD were examined
to verify whether the patient had achieved the state of
ID. In case the attending physician had started to de-
crease the weekly dosage or space dosing further apart
before the last follow-up visit because of achievement of
ID, the last observation in which the patient was still re-
ceiving the weekly dose was considered as the last fol-
low-up visit. In patients who achieved ID, the first visit
in which ID was documented was retained.
The state of ID was defined, according to Wallace cri-
teria [25], as no joint with active arthritis, no systemic
manifestations attributable to JIA, no active uveitis,
normal acute-phase reactants, and physician global as-
sessment of overall disease activity indicating no disease
activity (defined as score of 0 on a 0–10 visual analog
scale). However, in a number of patients the full set of
Wallace criteria could not be applied due to the lack of
the physician global assessment of disease activity. For
the visits in which this parameter was not available, but
the other Wallace criteria were met, the absence of
disease activity was inferred through the review of the
patient chart by consensus of two investigators (CB and
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FM). To substantiate this judgement, the caring phys-
ician who originally examined the patient at the time of
the visit was asked to review independently his/her notes
and to confirm the inactivity of the disease. Disagree-
ment between investigators and caring physician was
resolved by consensus.
Assessment of predictive factors
Variables recorded at the time of MTX start comprised
sex, age at disease onset, age and disease duration, ILAR
category, antinuclear antibody (ANA) status, route of
MTX administration, active joint count, erythrocyte
sedimentation rate (ESR), and C-reactive protein (CRP).
Predictive variables also included therapeutic interven-
tions made before MTX start and concomitant therapies
during MTX administration. Patient follow-up was
censored at the time of first occurrence of ID or, in case
ID was not achieved, at last follow-up visit or at the time
when a biologic DMARD was prescribed.
Statistics
Descriptive statistics were reported as medians and
interquartile ranges for continuous variables and as ab-
solute frequencies and percentages for categorical
variables. Comparisons between patients who did or did
not achieve ID were performed by Mann-Whitney U test
in case of quantitative data and chi-square test or
Fisher’s exact test, as appropriate, for categorical data.
Predictive factors were tested for association with lack
ofachievement of ID during the time of observation
through multiple logistic regression analysis, entering
explanatory variables that showed statistically (p < 0.05)
significant results in univariate tests or were considered
clinically meaningful. Cases with missing variables were
excluded from the analysis. Before the application of
logistic regression procedures, continuous variables, in-
cluding active joint count, ESR and CRP, were dichoto-
mized to binary variables. Cut-off points were obtained
through receiver operating characteristic (ROC) curve
analysis. The step-down strategy of analysis was chosen,
which consists of examining the effect of removing
variables from the saturated model.
To obtain a “prediction model” of lack of achievement
of ID, the regression coefficients (β) of predictive vari-
ables that entered the best-fitting logistic regression
model were converted into scores rounded to the near-
est 0.5 and then summed up to obtain a “prediction
score”. Finally, by means of the ROC curve method, the
cutoff score that discriminated best between patients
who achieved or did not achieve ID was calculated.
The statistical packages used were Statistica (version
9.0, StatSoft Corp.) for univariate analyses and Stata
(release 7, Stata Corp.) for multivariable analyses.
Results
Patient characteristics
A total of 406 patients were treated with MTX as the
sole DMARD in the study period. Thirty-one patients
were excluded from the analysis because the clinical
chart could not be retrieved or the follow-up period
after start of MTX was shorter than 6 months. None of
the patients had died due to disease complications, par-
ticularly macrophage activation syndrome. The main
demographic and clinical features of the remaining 375
patients are presented in Table 1. The patient sample was
characterized by marked prevalence of females, young age
at disease onset, and high frequency of positive ANA sta-
tus. The most common ILAR categories were oligoarthri-
tis (44.3%) and RF-negative polyarthritis (37.1%), followed
by systemic arthritis (7.7%), enthesitis-related arthritis
(ERA) (5.1%), undifferentiated arthritis (3.7%), RF-positive
polyarthritis (1.9%), and psoriatic arthritis (0.3%). Of the
166 patients with oligoarthritis, 24% had persistent oli-
goarthritis and 20.3% had extended oligoarthritis.
For the purpose of the analysis and according to
Beukelman et al. [26], patients were grouped in the func-
tional phenotypes of oligoarthritis (4 or fewer affected
joints), polyarthritis (5 or more affected joints), systemic
arthritis, and ERA. At treatment start, patients had on
average early disease, as shown by the median disease dur-
ation of 0.8 years and the median duration of follow-up at
our center of 0.2 months. Twenty-one of the 29 patients
with systemic arthritis had active systemic manifestations.
The median number of affected joints was 5 and the most
frequently involved joints were the ankle and the knee.
The MTX regimen, the therapeutic interventions
made before MTX start and the medications adminis-
tered concomitantly at treatment start or during MTX
therapy are shown in Table 2. MTX was started more
commonly subcutaneously than through the oral route
(55.9 vs 44.1%). Nearly half of the patients who were
started orally were subsequently switched to the paren-
teral route, most frequently due to insufficient efficacy.
Only a few patients had received corticosteroids, either
systemic or intra-articular, or other synthetic DMARDs
before the start of MTX. At MTX initiation, nearly two
third of the patients were receiving NSAIDs, 21.8% were
taking systemic corticosteroids, and around 40% were
given intra-articular corticosteroids. During MTX ad-
ministration, approximately 9% of the patients were pre-
scribed systemic corticosteroids and 44.1% underwent
intra-articular corticosteroid injections. The systemic
corticosteroid medication was prednisone in almost all
patients, whereas the corticosteroid preparation used for
intra-articular injections was triamcinolone hexacetonide
for large joints and methylprednisolone acetate for small
joints or for joints difficult to access clinically (e.g. the
subtalar and intertarsal joints) [27].
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Frequency of achievement of ID
A total of 229 (61%) patients achieved the state of ID
after a median of 1.7 years (IQR 1–2.5 years) from the
start of MTX, whereas 146 patients (39%) did not
achieve ID after a median of 1.2 years (IQR 0.5–2.6
years) of MTX therapy. In 48 (20.9%) of the 229 patients
with ID, this state could not be established formally
according Wallace criteria, owing to the lack of the
physician global assessment, but was inferred through
the review of clinical charts. This assessment was made
by the caring physicians for all 48 patients.
Comparison of the clinical characteristics between
patients with and without ID
The demographic, clinical, laboratory and therapeutic
features of patients who achieved or did not achieve ID
are reported in Tables 1 and 2. Compared with patients
who reached ID, those who did not were less frequently
Table 2 Therapeutic data of study patients considered as a whole and by achievement of ID
Therapeutic features All patients (n = 375) Patients who did not achieve
ID (n = 146)
Patients who achieved
ID (n = 229)
P#
Median MTX dose, mg/m2 (n = 339) 12.8 (11.1–14.5) 13.1 (11.6–14.5) 12.8 (10.9–14.3) 0.2
Route of MTX administration 0.04
Oral 162/367 (44.1) 53 (37.3) 109 (48.4)
Parenteral 205/367 (55.9) 89 (62.7) 116 (51.6)
Treatment before MTX start
Intra-articular corticosteroid injections 17/372 (4.6) 3/143 (2.1) 14 (6.1) 0.07
Systemic corticosteroids 29/372 (7.8) 22/143 (15.4) 7 (3.1) < 0.0001
Other synthetic DMARDs 21 (5.6) 14/143 (9.8) 7 (3.1) 0.006
Concomitant therapies during MTX administration
Intra-articular corticosteroid injections 165/374 (44.1) 67/145 (46.2) 98 (42.8) 0.52
Systemic corticosteroids 33/374 (8.8) 25/145 (17.2) 8 (3.5) < 0.0001
ID inactive disease, MTX methotrexate, DMARDs disease modifying antirheumatic drugs
#P value refers to the comparison between patients who did not achieve or achieved ID
Data are the number (%) unless otherwise indicated
Table 1 Baseline characteristics of study patients considered as a whole and by achievement of ID
Features All patients (n = 375) Patients who did not achieve
ID (n = 146)




Female 299 (79.7) 103 (70.5) 195 (85.6)
Male 76 (20.3) 43 (29.5) 33 (14.4)
Median (IQR) age at disease onset, yrs 3.2 (1.7–7.0) 4.4 (1.9–8.2) 2.7 (1.7–5.5) 0.002
Median (IQR) age, yrs 5.6 (3.0–9.5) 6.3 (3.3–9.9) 4.9 (2.8–9) 0.05
Median (IQR) disease duration, yrs 0.8 (0.4–2.4) 0.8 (0.3–2.5) 0.9 (0.4–2.4) 0.08
Median (IQR) follow-up time, yrs 1.5 (0.8–2.5) 1.2 (0.5–2.6) 1.7 (1–2.5) 0.002
Functional phenotypes§ < 0.0001
Systemic arthritis 29/373 (7.8) 25 (17.2) 4 (1.8)
Polyarthritis 151/373 (40.5) 59 (40.7) 92 (40.3)
Oligoarthritis 174/373 (46.6) 49 (33.8) 125 (54.8)
Enthesitis-related arthritis 19/373 (5.1) 12 (8.3) 7 (3.1)
Patients with positive ANA 264/371 (71.2) 79/133 (59.4) 185/226 (81.9) < 0.0001
Median (IQR) no. of active joints 5 (3–8) 5 (3–10) 5 (3–7) 0.51
Median (IQR) ESR, mm/h (n = 313) 40 (21–58) 46 (24–62) 35.5 (19–56) 0.02
Median (IQR) CRP, mg/dl (n = 315) 1.3 (0.5–3.6) 2 (0.5–4.4) 0.9 (0.5–3) 0.001
ID inactive disease, IQR interquartile range, ANA antinuclear antibodies, ESR erythrocyte sedimentation rate, CRP C reactive protein
#P value refers to the comparison between patients who did not achieve or achieved ID. §For the purposes of the study analyses, the ILAR categories of juvenile
idiopathic arthritis were grouped in functional phenotypes according to Beukelman et al. (ref. [26])
Data are the number (%) unless otherwise indicated
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females, were older at disease onset, had less frequently
oligoarthritis and more frequently ERA and systemic
arthritis, were less frequently ANA positive, were given
more commonly parenteral MTX, and had higher ESR
and CRP values. In addition, patients who did not attain
ID had received more frequently systemic corticosteroids
either before MTX start or during MTX administration.
There was no difference between the two groups in age
and disease duration at study entry, number of active
joints, and frequency of intra-articular corticosteroid
therapy either before MTX start or during MTX
therapy.
Results of multivariable analysis
For the multivariable analysis, complete data were avail-
able for 369 patients. However, 4 children with ERA and
axial disease were excluded from the analysis based on
the demonstrations in the adult literature that traditional
DMARDs are ineffective in the management of axial
spondyloarthritis. In addition, because the administra-
tion of corticosteroid therapy could simply reflect the
provider perception that the child had severe disease at
onset and did not constitute a disease characteristic, this
variable was not included in multivariable analysis. The
best-fitting model obtained through logistic regression
procedures, in which the lack of attainment of ID was
the dependent variable, is presented in Table 3. Inde-
pendent correlations with lack of achievement of ID
were identified for the functional categories of systemic
arthritis, ERA and polyarthritis (versus oligoarthritis)
and a CRP value greater than 1.4 mg/dl.
Development of the prediction model
The score assigned to each variable independently asso-
ciated with the lack of achievement of ID in multivari-
able analysis is shown in Table 3. Note that the score of
each functional phenotype is mutually exclusive. The
prediction score obtained though the sum of the individ-
ual scores ranged from 0 to 3. Sensitivity and specificity
were calculated for several cutoffs of the prediction
score, as shown in Table 4. The cutoff score that
discriminated best between patients who achieved or did
not achieve ID was > 0.5. Its sensitivity and specificity
were 54.8 and 66.4%, respectively. The assessment of ac-
curacy through the ROC curve analysis yielded an area
under the curve (AUC) of 0.64.
Discussion
In the present study, we investigated the frequency of at-
tainment of ID in 375 children with JIA seen between
2000 and 2013 who received MTX as the sole DMARD,
with or without concomitant administration of NSAIDs
or systemic or intra-articular corticosteroids. Of the two
routes of corticosteroid administration, the intra-articu-
lar one likely played a greater synergistic role with MTX
as 44.1% of patients were given corticosteroids intra-
articularly and only 8.8% systemically during MTX ad-
ministration. Patient follow-up was censored at the time
of the occurrence of the first episode of ID, at last fol-
low-up visit with persistently active disease, or when the
caring physician deemed necessary the start of a biologic
DMARD because of persistently active disease despite
MTX therapy. Thus, the results of our study provide in-
sights on the potential to achieve complete disease qui-
escence with conventional (i.e. non-biologic) treatment.
As such, they offer a measure against which outcomes
from other cohorts may be judged and a benchmarking
for outcome comparisons with recent cohorts treated
with more aggressive approaches, based on earlier intro-
duction of biologic DMARDs or with the treat-to-target
strategy [9, 28, 29].
We found that 61% of patients achieved ID after a me-
dian of 1.7 years from the start of MTX therapy. The
relative frequency of favorable outcome was higher
among patients with oligoarthritis than in those with
ERA or systemic arthritis; an equal proportion of pa-
tients with polyarthritis reached or did not reach ID.
Note that in the study period it was our policy to inject
with corticosteroids all active joints at presentations in
each patient with oligoarthritis. MTX was started at the
time of intra-articular therapy in most of these patients,
except those with knee monoarthritis who received their
Table 3 Regression logistic model for the lack of achievement of ID
β OR (95% CI) Pa Score
Functional phenotype (reference phenotype: oligoarthritis) < 0.0001
Polyarthritis 0.26 1.3 (0.8–2.1) 0.5
Enthesitis-related arthritis 1.37 3.9 (1.3–11.8) 1.5
Systemic arthritis 2.45 11.6 (3.7–36.0) 2.5
CRP > 1.4 mg/dl (reference category: ≤ 1.4 mg/dl) 0.60 1.8 (1.1–2.9) 0.014 0.5
Score range 0–3
ID inactive disease, OR Odds Ratio, 95% CI 95% Confidence Interval; aLikelihood Ratio Test; CRP C reactive protein
Complete data were available for 365 patients. This model was transformed, using the β regression coefficient, into a prediction score for the risk of lack of
achievement of ID. The area under the curve (AUC) of the model was 0.67.
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first injection [30]. The results of our study are not easily
comparable with those reported in other series of JIA
patients treated with MTX because of differences in
proportion of disease categories, length of follow-up,
treatment regimens, concomitant therapies and outcome
endpoints. In a recent German national multicenter
study, a similar proportion (68%) of biologic-naïve pa-
tients who were started with MTX experienced at least
one episode of ID [23].
In univariate analysis, patients of male gender and
with older age at disease onset, ERA or systemic arth-
ritis, absence of ANA, and higher ESR and CRP, and pa-
tients treated with parenteral MTX and given systemic
corticosteroids before and during MTX administration
were less likely to attain ID. The lesser responsiveness to
MTX of patients with systemic arthritis is in keeping
with the well-established notion that this JIA category is
scarcely susceptible to this drug, particularly in the pres-
ence of active systemic manifestations [31]. MTX is also
known to be distinctively less effective in ERA, for which
current therapeutic recommendations advice the use of
sulfasalazine as primary synthetic DMARD [26]. The
predictive role of male gender and older onset age is
likely related to that of systemic arthritis and ERA, in
which these features are more prevalent than in the
other forms of JIA. The relationship between absence of
ANA and poorer efficacy of MTX agrees with the previ-
ous demonstrations of ANA-positivity being a marker of
better response to MTX [13, 32–35]. Elevated acute
phase reactants were found by Bulatovìc et al. [35] to be
associated with lack of achievement of ID with MTX
therapy. The association of parenteral MTX with worse
outcome may reflect our policy to switch from the oral
to the parenteral route or to start MTX parenterally
in the most severe or refractory patients. Likewise,
patients treated with systemic corticosteroids were
those with systemic arthritis or more severe polyar-
thritis, who have an underlying high risk of poorer
therapeutic response.
The variables that remained independently associated
with lack of attainment of ID in the best-fitted model of
logistic regression procedures were systemic arthritis,
ERA, polyarthritis and elevated CRP. Based on the
results of multivariable analysis, we devised a predic-
tion score for lack of achievement of ID with MTX
as the sole DMARD, which ranged from 0 to 3. The
score cutoff that discriminated best between patients
who achieved or did not achieve ID was > 0.5, which
means that patients with a score ≥ 1 are less likely to
attain ID with MTX as the sole DMARD. Thus, a
diagnosis of systemic arthritis or ERA, both of which
had a score greater than 0.5, was sufficient alone to
predict a lower likelihood to reach ID. Polyarthritis
and increased CRP, whose score was 0.5, assumed a
predictive value only when present in association.
A number of caveats should be considered in inter-
preting our findings. The study design was retrospective,
which implies the risk of missing or possibly erroneous
data. Our results reflect a single-center experience,
which means that they may not be generalized to series
followed in other settings. Because our analysis was
nonrandomized and observational, we cannot exclude
that patients who achieved ID had a less aggressive
disease than those who did not. In this respect, the over-
representation of the oligoarticular phenotype, which is
regarded as the most benign JIA subset, might partly
explain the favorable outcome figures. The median time
interval of 1.7 years between MTX start and achieve-
ment of ID would nowadays be regarded as too long.
Contemporary treatment strategies mandate an earlier
achievement of complete disease control [9, 10]. We
recognize that the AUC of the predictive model as well
as the sensitivity and specificity of the score cutoff were
only fair. Thus, the prediction model needs to be tested
in a validation cohort prospectively. The use of logistic
regression cannot account for the different length of fol-
low-up time for each patient. A time-to-event hazard
model would have been more appropriate to address this
issue. Achievement of ID was only assessed at a sin-
gle point in time and not in terms of time spent in
ID. Several studies have shown a high risk of disease
flare after MTX discontinuation for clinical remission
in children with JIA [20, 23, 36]. We should finally
recognize that in a number of patients the state of ID
could not be established formally according Wallace
criteria, owing to the lack of the physician global
assessment, but was inferred through the review of
clinical charts.
Conclusions
In conclusion, we found that a conventional treatment
regimen based on the use of MTX as the sole DMARD
led to the achievement of ID in a sizeable proportion of
Table 4 Sensitivity and specificity for each score cutoff
Prediction score Sensitivity (%) Specificity (%)
= 0 100 0
> 0 86.3 21.8
> 0.5 54.8 66.4
> 1 28.8 90.8
> 1.5 23.3 95.6
> 2 17.1 98.3
> 2.5 11.6 98.7
Area under ROC curve: 0.64; 95% confidence interval: 0.59–0.69
The best score cut-off value is > 0.5. A score > 0.5 had the best capacity to
identify patients who did not reach inactive disease
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children with JIA. Patients with systemic arthritis,
ERA and polyarthritis with increased CRP were less
likely to achieve ID. These findings help to outline
the characteristics of JIA patients who may deserve
the prescription of a synthetic DMARD other than
MTX or the introduction of a biologic DMARD from
the disease outset.
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